Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors.

[1]  L. Dirix,et al.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Dowsett,et al.  A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Piccart,et al.  The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Blankenstein,et al.  Intratumoral levels of estrogens in breast cancer , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  P. Lønning,et al.  In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  D. Campos,et al.  Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Barni,et al.  A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Cavalli,et al.  Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK) , 1997, European journal of cancer.

[10]  J. Thijssen,et al.  Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. , 1997, Cancer research.

[11]  L. Mariani,et al.  The minimal effective exemestane dose for endocrine activity in advanced breast cancer. , 1997, European journal of cancer.

[12]  P. Lønning,et al.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.

[13]  G. Hortobagyi,et al.  Aromatase inhibitors in metastatic breast cancer. , 1996, Seminars in oncology.

[14]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Lønning.  Pharmacology of new aromatase inhibitors , 1996 .

[16]  M. Dowsett.  Biological background to aromatase inhibition , 1996 .

[17]  G. Chetrite,et al.  Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. , 1996, The Journal of clinical endocrinology and metabolism.

[18]  M. Castiglione‐Gertsch.  New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity. , 1996, European journal of cancer.

[19]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  L. Mariani,et al.  Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. , 1995, British Journal of Cancer.

[22]  C. Bartoli,et al.  Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. , 1994, British Journal of Cancer.

[23]  G. Aherne,et al.  Concentrations of oestrone and 4‐hydroxyandrostenedione in malignant and normal breast tissues , 1991, International journal of cancer.

[24]  W. Miller,et al.  The importance of local synthesis of estrogen within the breast , 1987, Steroids.

[25]  W. Bezwoda,et al.  Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. , 1987, Oncology.

[26]  W. Yue,et al.  Intratumoral aromatase model: The effects of letrozole (CGS 20267) , 2004, Breast Cancer Research and Treatment.

[27]  I. Tannock,et al.  Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Per E. Loünning.  Aromatase inhibition for breast cancer treatment. , 1996 .

[29]  P. Lønning,et al.  The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. , 1992, European journal of cancer.

[30]  M. Dowsett,et al.  4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. , 1992, European journal of cancer.